NCT06521827Not yet recruiting
The Role of Short Course of Palliative Radiation in Metastatic Cancer Rectum
Source: ClinicalTrials.gov · Last updated 26 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Short-course radiotherapy (SCRT), which allows the delivery of 25 Gy in five daily fractions, has emerged as an attractive strategy for rectal cancer treatment. Surgery can safely be deferred after SCRT, allowing an opportunity to deliver chemotherapy (ChT) preoperatively rather than postoperatively. In cases of metastatic disease, this represents an effective treatment option to improve local control and avoid colostomy in a subset of patients.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- First submitted
- 17 Jul 2024
- Start date
- Aug 2024
- Primary completion date
- Aug 2024
- Lead sponsor
- Assiut University
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT06521827
What you commit to
- Study type: Interventional
- Planned participants: 49
- From Aug 2024 to the primary completion date, Aug 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy.
- Concomitant chemotherapy.
- Previously created stoma.
Who the study is looking for
- Adenocarcinoma pathological evidence in rectal carcinoma.
- Metastatic unresectable rectal cancer.
- Symptomatic disease for at least one of the following signs: bleeding, pain, tenesmus, obstruction,
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.